Evidence map›Paper›PMID 36763109›Full record

ArticleAnnals of hematology2023

Improved Vδ2

Keli Yue, Haitao Gao, Shuang Liang, Ning Wu, Cong Cheng, Lan-Ping Xu, Xiao-Hui Zhang, Yu Wang, Yifei Cheng, Xiao-Jun Huang and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Keli YuePeking University People's Hospital, Peking University Institute of Hematology, 11 Xizhimen South Street, Beijing, 100044, China.
Haitao GaoPeking University People's Hospital, Peking University Institute of Hematology, 11 Xizhimen South Street, Beijing, 100044, China.
Shuang LiangPeking University People's Hospital, Peking University Institute of Hematology, 11 Xizhimen South Street, Beijing, 100044, China.
Ning WuPeking University People's Hospital, Peking University Institute of Hematology, 11 Xizhimen South Street, Beijing, 100044, China.
Cong ChengPeking University People's Hospital, Peking University Institute of Hematology, 11 Xizhimen South Street, Beijing, 100044, China.
Lan-Ping XuPeking University People's Hospital, Peking University Institute of Hematology, 11 Xizhimen South Street, Beijing, 100044, China.
Xiao-Hui ZhangPeking University People's Hospital, Peking University Institute of Hematology, 11 Xizhimen South Street, Beijing, 100044, China.
Yu WangPeking University People's Hospital, Peking University Institute of Hematology, 11 Xizhimen South Street, Beijing, 100044, China.
Yifei ChengPeking University People's Hospital, Peking University Institute of Hematology, 11 Xizhimen South Street, Beijing, 100044, China.
Xiao-Jun HuangPeking University People's Hospital, Peking University Institute of Hematology, 11 Xizhimen South Street, Beijing, 100044, China.
Jiangying LiuPeking University People's Hospital, Peking University Institute of Hematology, 11 Xizhimen South Street, Beijing, 100044, China. xys_liujiangying@pkuph.edu.cn.ORCID http://orcid.org/0000-0002-6437-4330
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) patients can benefit from allogeneic hematopoietic cell transplantation (alloHCT) and achieve long-term remission. Recovery of T cell quantity and quality is critical to reduce the incidences of life-threatening complications after alloHCT. Although the general recovery level of γδ T cells is recognized to be associated with outcomes of patients who suffered from various hematological diseases and received alloHCT, the correlation between γδ T cell subsets and the prognosis in AML patients following transplantation remains to be investigated. In the current study, the recoveries of T cell subpopulations in 103 AML patients were dissected at different time points after haploidentical HCT (haploHCT). Statistical analyses showed that the absolute number of Vδ2

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteChronic DiseaseHumansIncidenceRecurrenceTransplantation, HomologousAcute myeloid leukemiaHematopoietic cell transplantationImmune recoveryOverall survivalRelapseVδ2+ T cells

Identifiers

PMID36763109
OpenAlexW4319812517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.